Latest news with #SELECT
Scotsman
6 days ago
- Business
- Scotsman
UK Government's immigration plans could be ‘ticking time bomb' for Scottish construction
Trade association warns that potential exodus of industry professionals to England will leave nation 'bereft of skills' and damage transition to net zero Sign up to our daily newsletter – Regular news stories and round-ups from around Scotland direct to your inbox Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... The UK Government's tough new immigration proposals are 'a ticking time bomb' for Scottish construction which could cause an exodus of skilled workers and leave the sector with a massive skills gap, Scotland's largest trade association has warned. SELECT says the proposals to raise the qualification standards for foreign workers is likely to see a significant number abandoning the UK and returning home, with Scottish construction workers flooding south to fill the resulting shortage south of the Border. Advertisement Hide Ad Advertisement Hide Ad The electrotechnical body also echoed a shock new report issued this week by insisting that leaving the country 'bereft of skills' would also impact Scotland's transition to net zero, with fewer qualified professionals left to install and maintain renewable technology. Alan Wilson, Managing Director at SELECT SELECT Managing Director Alan Wilson raised the concerns with First Minister John Swinney during a meeting of Scottish business leaders last week, during which he relayed apprehensions from across the construction sector. Mr Wilsonsaid: 'Raising the thresholds for skilled workers may seem on the face of it to be a laudable aim, but it is likely to be detrimental to recruitment in the major UK population areas and that means workers will be sucked in from places like Scotland. 'In areas such as London, it's estimated that 50% of the workforce are from abroad, so if they leave, Scottish workers are likely to flood south to take up highly-paid jobs, leaving the domestic construction sector in crisis Advertisement Hide Ad Advertisement Hide Ad 'This could leave Scotland bereft of skills, with no opportunity to top up from abroad, and could lead to the worst of all possible worlds just as we need these skills to fulfil our transition to a net zero economy. 'This ticking time bomb could leave Scotland without enough skilled workers to build the country we need, which is why we had to bring it to the attention of government at the highest level.' The UK Government published its white paper policy document, Restoring control over the immigration system, on 12 May, proposing changes to make it harder to move to and settle in the UK, with a view to reducing immigration Under the proposals, Labour is proposing to raise the threshold for skilled workers from Regulated Qualifications Framework 3 (RQF3) – equivalent to Scottish Highers – to RQF6, which is degree level. Advertisement Hide Ad Advertisement Hide Ad Mr Wilson says many existing qualified tradespeople will be outwith the new threshold and insists the move will also be detrimental to recruitment, with firms less willing to recruit apprentices, creating a long-term impact on the sector. He said: 'We are facing a crisis in recruitment in almost all trades which will not be helped by the uncertainty caused by these proposals. 'The construction sector is a vital pillar of the Scottish economy, supporting infrastructure development, housing delivery and the green transition, yet it is experiencing a persistent and growing skills shortage already. 'According to the Construction Industry Training Board, an additional 26,100 workers will be needed across Scotland between 2024 and 2028 to meet demand, yet apprenticeship starts across construction have remained flat, with only around 6,500 new entrants per year.' Advertisement Hide Ad Advertisement Hide Ad Mr Wilson's warning comes after a new report by Aberdeen & Grampian Chamber of Commerce shows the UK is losing the skills and supply chain needed to deliver net zero, with a growing share of energy sector jobs, investment and innovation shifting abroad. The 41st Energy Transition Survey of more than 100 firms shows that two-thirds expect to increase their headcount overseas in the next five years, with almost half saying staff were already leaving the UK to work in other energy regions. Mr Wilson – who chairs the Construction Industry Collective Voice – also pointed out that architecture schools in Scotland, who often rely on fees from abroad, may have to shut down if students choose not to study there as a result of post-qualification uncertainty. He added: 'The uncertainty the proposals contain will be particularly acute for both graduate visa holders completing their training and employers, who may see no reward in investing in graduates from abroad qualifying in Scotland. Advertisement Hide Ad Advertisement Hide Ad 'Similarly, students may not choose to study architecture in Scotland because of the uncertainties post-qualification employment. This could have significant knock-on effects for architecture schools who rely on foreign students fees to make the courses viable.
Yahoo
08-05-2025
- Business
- Yahoo
Il Bottaccio, Relais & Châteaux Joins SELECT Hotels & Resorts by Internova Program
Collection includes more than 1,700 luxury properties that provide guests with special amenities MONTIGNOSO, Italy, May 8, 2025 /PRNewswire/ -- Il Bottaccio, Relais & Châteaux has been invited to join Internova Travel Group's SELECT Hotels & Resorts by Internova program, an exclusive collection of more than 1,700 luxury properties around the world. "We are excited to become part of the SELECT Hotels & Resorts by Internova family," said Mr. Antonio Mosca, General Manager of Il Bottaccio. "These properties maintain the highest standards of comfort and service, and it's an honor to be included. Internova travel advisors are known for going the extra mile for their clients and we do the same for our guests, so we're delighted to be partners with them. We look forward to offering their clients the special amenities that will make their stay with us even more memorable." Tucked away in a tranquil corner at the foot of the Apuan Alps, Il Bottaccio comes with its fair share of exciting history. It all started with a late 18th century mill, put in place by a wealthy citizen, Paquale Boldrini, who built a house around it in Montignoso. The name itself is quintessentially Tuscan and it refers to a basin where water is collected to supply mills and olive presses. Over the years, this fascinating building was acquired by a renowned heart surgeon, Gaetano Azzolina, who restored it and embellished it as a private home in the 1970s. Elio d'Anna, a mercurial, brilliantly witty, illuminated musician, philosopher and entrepreneur subsequently acquired it. The hotel opened in 1983 and entered the prestigious Relais&Chateau family in 1988. A home rather than a hospitality business, the idea behind it all was – and still is – that of offering respite and pleasure to gourmet travellers in search of matchless sensory experiences. The general atmosphere is one of enticing elegance and charm, epitomised by the highly unique décor, and yet an overall sense of familiarity embraces you as you step in, making every stay a memorable one. "We are thrilled to welcome Il Bottaccio, Relais & Châteaux into the SELECT Hotels & Resorts by Internova program," said Albert Herrera, Executive Vice President, Partner Relations for Internova Travel Group. "This is a carefully curated group of premium properties that offer exclusive privileges to our travelers. Our travel advisors know that their clients will enjoy a truly amazing experience when they stay at Il Bottaccio, Relais & Châteaux." Guests who book their stay at a SELECT hotel or resort by Internova through a travel advisor with ALTOUR, Andrew Harper, Global Travel Collection, Nexion Travel Group or Travel Leaders Network can enjoy amenities that are unique to the program. Based on availability, those perks may include resort credits, room upgrades, complimentary breakfast, early check-in and late check-out and basic Wi-Fi. To learn more about the SELECT Hotels & Resorts by Internova program, please visit About Il Bottaccio, Relais & ChâteauxNestled in the heart of Tuscany, Il Bottaccio Art Hotel is a haven of elegance and serenity, set within a beautifully restored 18th-century water mill. This exclusive retreat offers a refined yet intimate atmosphere, where history, art, and hospitality blend seamlessly to create an unforgettable experience. With only eight spacious and exquisitely designed suites, Il Bottaccio ensures the highest level of privacy and comfort. Each suite is a masterpiece, adorned with curated artworks, antique furnishings, and bespoke details that reflect the property's rich heritage and artistic soul. The warm ambiance, paired with modern amenities, creates the perfect balance between tradition and contemporary luxury. FACT SHEET Il Bottaccio is open year-round and has never closed since 1983. Guest amenities include a full service gourmet restaurant, Il Bottaccio Lounge Bar, a seasonal indoor pool, a beautiful garden and Otzium Wellness. Since 1st March 2022, the property only uses green energy and sets a high value on eco-sustainability and biodegradable measures. The unique setting of Il Bottaccio, suspended among the sea nearby and the Apuanian Alps, contributes to its original cuisine where the sea flavours combine with the musky aromas of the woods and the mountains. The food retains the Mediterranean light - airy and delicate, full-bodied and light. The perceptions, sensations and the emotions, which the place inspires, add a unique flavour to the food - Il Bottaccio has the quintessential qualities that turn professional catering into a form of Art. Ownership, Elio D'AnnaGeneral Manager and Executive Chef, Antonio MoscaLocation: Via Bottaccio, 1 - Montignoso - 54038 (MS), TuscanyContact:+39 0585 About Internova Travel GroupInternova Travel Group is one of the largest travel services companies in the world with a collection of leading brands delivering high-touch, personal travel expertise to leisure and corporate clients. Internova manages leisure, business and franchise firms through a portfolio of distinctive divisions. Internova represents more than 100,000 travel advisors in over 6,000 company-owned and affiliated locations predominantly in the United States, Canada and the United Kingdom, with a presence in more than 80 countries. CONTACTS:Irina Manolea Email: Phone: +39 0585 340031 Elizabeth GaerlanEmail: egaerlan@ Phone: +1 212 944-1125 View original content to download multimedia: SOURCE Internova Travel Group Sign in to access your portfolio
Yahoo
06-05-2025
- Health
- Yahoo
Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
Novo Nordisk A/S Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 – covering burden, and the value of treatment and prevention Analysis of the landmark SELECT trial to uncover new insights into the early cardiovascular benefits of semaglutide Real-world studies reinforce value of semaglutide in obesity Bagsværd, Denmark, 6 May 2025 – Novo Nordisk today announced that new data spanning the company's industry-leading portfolio across metabolic and cardiovascular health will be presented at the upcoming 32nd European Congress on Obesity (ECO), 11–14 May 2025. The data will further extend the wide-ranging evidence base for semaglutide through real-world evidence studies and additional analysis of the landmark cardiovascular outcomes trial, SELECT, as well as part 1 of the phase 3 ESSENCE trial in metabolic dysfunction-associated steatohepatitis (MASH). Data will also be presented on the wider societal impacts of treating and preventing obesity, alongside analysis of the burden of obesity in adolescents. 'Obesity is one of the greatest healthcare challenges we face globally, impacting the lives of hundreds of millions of people. Without effective interventions, the global burden of obesity and its complications will continue to rise,' said Stephen Gough, senior vice president and head of Chief Medical Office at Novo Nordisk. 'Our broad and robust semaglutide data presented at ECO, including its impact on weight loss in a real-world setting and its early clinical effect on cardiovascular events and death, significantly adds to the growing body of evidence showing the value of semaglutide to individuals, healthcare systems and society.' 'We are dedicated to leading the way in defeating obesity and are pleased to return to ECO to present new, strong semaglutide data,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'Our investment into the understanding and treatment of obesity continues to reveal new insights, with semaglutide showing its potential to improve health in obesity, heart disease and liver disease. Our data shows that semaglutide provides early protection against heart disease even before significant weight loss occurs and that for people in treatment, our digital support solutions have the potential to enhance weight loss further.' Novo Nordisk abstracts to be presented, some of these data for semaglutide are investigational: Abstract Title Abstract presentation details Estimating the effect of overweight and obesity during adolescence on the risk of long-term comorbidities: a population-based retrospective analysis in England between 2008 and 2023 Oral Presentation (AD07.05) S Senniappan (UK) 12 May, 12:30–12:45 CEST Estimating the prevalence of overweight and obesity and the incidence of comorbidities in adolescents living with overweight and obesity: a cohort study using routinely collected healthcare data in England between 2008 and 2023 Poster presentation (PO3.038) 12 May, 18:00-19:30 CEST Association between engagement with the WegovyCare digital self-support app and weight loss in a real-world setting Oral presentation (AD12.06) B L Heitmann (Denmark) 13 May, 12:45–13:00 CEST Early Clinical Benefit of Semaglutide in Adults with Overweight or Obesity and Cardiovascular Disease: A Secondary Analysis of the SELECT Trial Oral Presentation (AD15.04) J Plutzky (US) 13 May, 17:15–17:30 CEST Use and Effectiveness of Once-weekly Semaglutide in US Adults with Overweight or Obesity in Clinical Practice Poster presentation (PO4.070) 13 May 18:00–19:30 CEST A personalized treat-to-target approach for obesity management: Integrating changes in adiposity measures with changes in biomarker levels towards reaching low-risk states of incident T2D and ASCVD Poster presentation (PO4.171) 13 May, 18:00–19:30 CEST What are the most important research questions within prediabetes? A Priority Setting Partnership in collaboration with patients, healthcare professionals and researchers Poster presentation (PO4.194) 13 May, 18:00-19:30 CEST Metrics that matter: identifying endpoints for capturing the broad health impacts of obesity prevention Poster presentation (PO2.058) 13 May A novel framework to assess the prevention value of a health intervention Poster presentation (PO4.143) 13 May Weight-independent benefits of semaglutide on histology and non-invasive tests in participants with biopsy-defined MASH: Post hoc analysis of the ESSENCE trial part 1 Oral Presentation (Part of accepted scientific symposium: The MASH – Obesity intersection) P Newsome (UK) 14 May, 09:30–11:00 (presentation time 10:15-10:40) CEST Predicting weight loss using self-reported, digitally collected, real-world data after initiation of semaglutide treatment Poster presentation (PO4.095) Quantifying the Productivity Gains of Semaglutide Treatment in the UK for the Population Eligible for Reimbursement: a Modelling Study Using the Wider Societal Impacts Framework Poster presentation (PO4.194) Obesity is a chronic, multi-factorial disease influenced by biological, psychological, and environmental factors that often puts people on the pathway to other serious chronic diseases, including cardiovascular disease (CVD) and metabolic diseases, such as type 2 diabetes, obesity, and MASH.1,2,3 A significant proportion of the cardiovascular risk associated with these diseases is attributable to shared metabolic risk factors.3 CVD accounts for around 70% of deaths in people living with obesity and is the leading cause of death in people with type 2 diabetes, chronic kidney disease and MASH.3, 4, 5, 6
Qatar Tribune
04-05-2025
- Health
- Qatar Tribune
Aamal, Novo Nordisk join forces to bring weight management drug Wegovy to Qatar
Tribune News Network Doha Ebn Sina Medical, a subsidiary of Aamal Company and a leading supplier of pharmaceutical, and Novo Nordisk, the Danish leading global healthcare company renowned for its expertise in treating chronic diseases such as diabetes and obesity, announced the availability of Wegovy (Semaglutide 2.4mg) in Qatar. The event was attended by HE Anders Bjørn Hansen, the Ambassador of Denmark to the UAE and Qatar, Aamal Company CEO Rashid Al Mansoori, in the presence of Manvendra Singh, General Manager of Novo Nordisk Qatar and Dr. Nayla Mansour, Commercial Director on behalf of Essam Faragalla, General Manager of Ebn Sina Medical. Wegovy (Semaglutide 2.4mg), the first and only once-weekly GLP-1 receptor agonist (GLP-1RA) indicated for chronic weight management in adults and adolescents ages 12 years and above1, is now available in Qatar. Obesity has emerged as a significant global epidemic, affecting approximately 1 billion individuals world-wide2. Obesity in the Gulf is rapidly unfolding with the highest rates globally3. In Qatar, the obesity crisis is particularly severe, the current prevalence of obesity (body mass index [BMI] ≥ 30 kg/m2) amongst adults in Qatar is estimated to be 41% with a notably higher prevalence amongst women (46%) and, nearly 76% of individuals in Qatar are classified as overweight; this places Qatar among the top 10 highest obesity rates in the world4,5,. The high rates of obesity and overweight in Qatar are linked to the high-country overall rates of related chronic conditions such as pre-diabetes, diabetes and cardiovascular diseases (CVDs) 6. The active ingredient in Wegovy, Semaglutide 2.4 mg, works by reducing hunger and increasing the feeling of fullness 1,7. Wegovy is indicated as adjunct to reduced calorie intake and increased physical activity for weight management, including weight loss and weight maintenance in adults with obesity (BMI ≥ 30 kg/m2) or with overweight (BMI ≥ 27 kg/m2) in the presence of at least one weight-related comorbidity. As per clinical research, Wegovy on top of diet and exercise delivers 17% mean weight loss sustained over 2 years with one third of patients having a reduction of at least 20% body weight loss 1,8,9,10. Semaglutide 2.4 mg demonstrated significant improvements in other cardiometabolic risk factors such as: waist circumference, blood pressure, lipid profile, Glycemic parameters & C-reactive protein. The SELECT clinical study including 17,604 adults with a BMI ≥27 kg/m2 demonstrated that Semaglutide 2.4 mg resulted in a statistically significant 20% risk reduction in Major Adverse Cardiovascular Events (MACE) in people with overweight or obesity and established CVD, without T2DM1,15. Besides its indication in adults, Wegovy is also approved as the first and only once weekly GLP-1 receptor agonist (GLP-1RA) for chronic weight management in adolescents with obesity from the age of 12 years1. This innovation may help transform the medical management of adolescent obesity in Qatar, where nearly 20% of children and adolescents are affected.6;11 During the event, Rashid bin Ali Al Mansoori, Aamal Company CEO, welcomed the attendees and highlighted this major step forward in addressing this public health challenge. He emphasized Aamal's commitment to advancing healthcare innovation and infrastructure in Qatar, through its subsidiaries such as Ebn Sina Medical in alignment with the country's National Health Strategy and Vision 2030, and reaffirmed Aamal's dedication to supporting access to the latest healthcare solutions that can positively impact the lives of individuals and the health of our wider community. From Novo Nordisk's side, Manvendra Singh, General Manager Novo Nordisk Qatar said: 'At Novo Nordisk, we are proud to bring over 100 years of global leadership in chronic disease management and 25 years of dedicated obesity research to Qatar. The availability of Wegovy marks a significant step in addressing obesity as a serious, chronic disease. As Qatar continues to face high rates of obesity, diabetes, and cardiovascular disease, our collaboration with Ebn Sina is vital. Together, we are committed to strengthening the healthcare landscape and improving patient outcomes through innovative, science-driven solutions.' Ebn Sina Medical General Manager Essam Faragalla added: 'At Ebn Sina Medical, we are committed to ensuring that the people of Qatar have access to world-class healthcare solutions. This partnership with Novo Nordisk marks a significant milestone in our journey to address the rising prevalence of obesity and related health complications in the country. We enjoy a long-standing relationship with Novo Nordisk and share a unified vision to prioritize patient-centric care. The introduction of Wegovy reflects our continuous drive to deliver innovative treatments and reinforces our role as a trusted healthcare partner aligned with Qatar's National Health Strategy.'
Zawya
01-05-2025
- Health
- Zawya
Ebn Sina Medical strengthens commitment to healthcare innovation
Doha: Ebn Sina Medical, a subsidiary of Aamal Company Q.P.S.C. and a leading supplier of pharmaceutical, and Novo Nordisk, the Danish leading global healthcare company renowned for its expertise in treating chronic diseases such as diabetes and obesity, announced the availability of Wegovy® (Semaglutide 2.4mg) in Qatar. The event was attended by H.E. Mr. Anders Bjørn Hansen, the Ambassador of Denmark to the UAE and Qatar, Aamal Company CEO Mr. Rashid Al Mansoori, in the presence of Mr. Manvendra Singh, General Manager of Novo Nordisk Qatar and Dr. Nayla Mansour, Commercial Director on behalf of Mr. Essam Faragalla, General Manager of Ebn Sina Medical. Wegovy® (Semaglutide 2.4mg), the first and only once-weekly GLP-1 receptor agonist (GLP-1RA) indicated for chronic weight management in adults and adolescents ages 12 years and above1, is now available in Qatar. Obesity has emerged as a significant global epidemic, affecting approximately 1 billion individuals world-wide2. Obesity in the Gulf is rapidly unfolding with the highest rates globally3. In Qatar, the obesity crisis is particularly severe, the current prevalence of obesity (body mass index [BMI] ≥ 30 kg/m2) amongst adults in Qatar is estimated to be 41% with a notably higher prevalence amongst women (46%) and, nearly 76% of individuals in Qatar are classified as overweight; this places Qatar among the top 10 highest obesity rates in the world4,5,. The high rates of obesity and overweight in Qatar are linked to the high-country overall rates of related chronic conditions such as pre-diabetes, diabetes and cardiovascular diseases (CVDs) 6. The active ingredient in Wegovy®, Semaglutide 2.4 mg, works by reducing hunger and increasing the feeling of fullness 1,7. Wegovy® is indicated as adjunct to reduced calorie intake and increased physical activity for weight management, including weight loss and weight maintenance in adults with obesity (BMI ≥ 30 kg/m2) or with overweight (BMI ≥ 27 kg/m2) in the presence of at least one weight-related comorbidity.1 As per clinical research, Wegovy® on top of diet and exercise delivers 17% mean weight loss sustained over 2 years with one third of patients having a reduction of at least 20% body weight loss 1,8,9,10. Semaglutide 2.4 mg demonstrated significant improvements in other cardiometabolic risk factors such as: waist circumference, blood pressure, lipid profile, Glycemic parameters & C-reactive protein. 1,10,11,12 The SELECT clinical study including 17,604 adults with a BMI ≥27 kg/m2 demonstrated that Semaglutide 2.4 mg resulted in a statistically significant 20% risk reduction in Major Adverse Cardiovascular Events (MACE) in people with overweight or obesity and established CVD, without T2DM1,15. Besides its indication in adults, Wegovy® is also approved as the first and only once weekly GLP-1 receptor agonist (GLP-1RA) for chronic weight management in adolescents with obesity from the age of 12 years1. This innovation may help transform the medical management of adolescent obesity in Qatar, where nearly 20% of children and adolescents are affected.6;11 During the event, Mr. Rashid bin Ali Al Mansoori, Aamal Company CEO, welcomed the attendees and highlighted this major step forward in addressing this public health challenge. He emphasized Aamal's commitment to advancing healthcare innovation and infrastructure in Qatar, through its subsidiaries such as Ebn Sina Medical in alignment with the country's National Health Strategy and Vision 2030, and reaffirmed Aamal's dedication to supporting access to the latest healthcare solutions that can positively impact the lives of individuals and the health of our wider community. From Novo Nordisk's side, Mr. Manvendra Singh, General Manager Novo Nordisk Qatar said: 'At Novo Nordisk, we are proud to bring over 100 years of global leadership in chronic disease management and 25 years of dedicated obesity research to Qatar. The availability of Wegovy® marks a significant step in addressing obesity as a serious, chronic disease. As Qatar continues to face high rates of obesity, diabetes, and cardiovascular disease, our collaboration with Ebn Sina is vital. Together, we are committed to strengthening the healthcare landscape and improving patient outcomes through innovative, science-driven solutions.' Ebn Sina Medical General Manager Mr. Essam Faragalla added: 'At Ebn Sina Medical, we are committed to ensuring that the people of Qatar have access to world-class healthcare solutions. This partnership with Novo Nordisk marks a significant milestone in our journey to address the rising prevalence of obesity and related health complications in the country. We enjoy a long-standing relationship with Novo Nordisk and share a unified vision to prioritize patient-centric care. The introduction of Wegovy® reflects our continuous drive to deliver innovative treatments and reinforces our role as a trusted healthcare partner aligned with Qatar's National Health Strategy.' Prof. Usama ALAlami; Head of Medical; Novo Nordisk Qatar highlighted: 'Obesity is the leading cause for many complications and it's the main driver of the diabetes epidemic in Qatar, accounting for 57.5% of diabetes 2 Diabetes (T2DM) and cardiovascular diseases (CVDs) are the greatest contemporary health challenges globally, and there is an urgent need to prevent future increase in new cases and new complications of obesity13. Data on Semaglutide 2.4mg® are reassuring with clinically significant weight loss in people with obesity or overweight. Based on trials' outcome, 80% of those who were with pre-diabetes regressed to normoglycemia9, which suggests that Semaglutide 2.4 mg could help prevent T2D in high-risk people with obesity or overweight'.8,1 About Ebn Sina Medical: Ebn Sina Medical,is a subsidiary of Aamal Company, and it is considered a leading supplier of pharmaceutical supplies, hospital supplies, and health products to consumers in Qatar, with contracts with more than 70 leading international healthcare manufacturers from more than 20 countries. Ebn Sina Medical also operates a chain of pharmacies bearing the name Ebn Sina Pharmacy and three-Foot Care Centers. Ebn Sina Medical has successfully established several strategic partnerships with suppliers, which has enabled the company to diversify its service offering in terms of generic and biosynthetic drugs. Ebn Sina Medical continues to innovate and drive efficiency installing a robot at its warehouse to enable drugs to be handled quickly and accurately. Please visit About Aamal Company Q.P.S.C Aamal is one of the region's most diversified conglomerates and has been listed on the Qatar Stock Exchange since December 2007. As of x May 2025, the Company had market capitalisation of QAR xxbn (US$ xxbn). Aamal's operations are widely diversified and comprise 32 active business units (subsidiaries and joint ventures) with market leading positions in the key industrial, retail, property, managed services, and medical equipment and pharmaceutical sectors, thereby offering investors a high quality and balanced exposure to Qatar's wider economic growth and development. For further information on Aamal Company, please refer to the corporate website: About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contact Aamal Company: Laura Ackel Corporate Communications Officer Email: Contact Novo Nordisk Email: ( References: Wegovy® [summary of product characteristics]. Approved in Qatar October 2024 World Obesity federation. Available at: Accessed on 26 September 2024. World Health Organization. Global Health Observatory (GHO) data. Overweight and obesity. [cited 2020 05 August]. World Obesity Federation. World Obesity Atlas 2024. London: World Obesity Federation, 2024. Accessed on 29 September 2024. Haj Bakri, A. et al. Chronic disease risk factor surveillance: Qatar STEPS report 2012. Qatar: The Supreme Council of Health. Obesity in Qatar: current and future strategies, Taheri, Shahrad et al. The Lancet Diabetes & Endocrinology, Volume 9, Issue 9, 561 – 562, 2021. Anam, M., Maharjan, S., Amjad, Z., et al. (2022). Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs). Cureus, 14(12), e32610. Colin IM, Gérard KM. Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer? touchREV Endocrinol. 2022 Jun;18(1):35-42. doi: 10.17925/EE.2022.18.1.35. Epub 2022 Jun 15. PMID: 35949360; PMCID: PMC9354513 Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11): 989-1002. D Weghuber et al, N Engl J Med 2022;387:2245-2257, DOI: 10.1056/NEJMoa2208601, VOL. 387 NO. 24 Awad SF, O'Flaherty M, Critchley J, Abu-Raddad LJ. Forecasting the burden of type 2 diabetes mellitus in Qatar to 2050: A novel modeling approach. Diabetes Research and Clinical Practice 2018;137:100-8 Qatar National Diabetes Strategy; (Accessed 14 Sep 2024) Roth GA et al. J Am Coll Cardiol 2020;76:2982–3021 Lincoff AM et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232.
